Stopped The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union
Conditions
Chronic Plaque Psoriasis
Interventions
DRUG: Efalizumab - anti CD11a recombinant human monoclonal antibody